Enhertu (fam-trastuzumab deruxtecan-nxki) has received FDA approval for HR-positive, HER2-low, HER2-ultralow metastatic breast cancer.

Dr. Debu Tripathy discusses the FDA approval of Enhertu in unresectable or metastatic hormone receptor HR+, HER2-low or -ultralow breast cancer. On Jan. 27, the Food and Drug Administration (FDA) ...

Enhertu currently costs around Rs 1.6 lakh per 100-milligram injection. Kindly note the image has been posted only for representational purposes. Photograph: Kind courtesy Thirdman/Pexels.com With ...

Just days after the FDA approved AstraZeneca and Daiichi Sankyo's Enhertu for a potentially lucrative new use, the regulatory has now cleared a diagnostic test that could help unlock the drug's ...

Reddit (RDDT) stock fell as much as 12% in after-hours trading Wednesday following the company's mixed fourth quarter earnings results. While the social media platform's fourth quarter revenue of ...

Super Micro Computer (SMCI) stock seesawed Tuesday after market close as the company said it expects to submit delayed filings to the SEC by the Nasdaq's Feb. 25 deadline to avoid delisting.

A recap of some of the top stories to read during Tuesday's trading: ...

In February, AstraZeneca and Daiichi Sankyo teased the results of their pivotal trial of Enhertu in HER2-low breast cancer, and, at ASCO, they finally revealed the data – with the numbers every ...

Here is how the Barron’s Roundtable members’ picks performed. Find investment ideas for your portfolio with the latest stock picks from Barron’s below. These picks are the product of the ...

U.S. Bancorp Dep. Pfd. (Rep. 1/1000th Non-Cum. Perp. Pfd. Series K) 0.80% U.S. Bancorp Dep. Pfd. (Rep. 1/1000th Perp. 3.75% Pfd. Series L) 0.67% U.S. Bancorp Dep. Pfd ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...